FDA Approves Once-Weekly Carfilzomib Regimen for Myeloma

October 1, 2018 – The FDA has approved a once-weekly dosing option of carfilzomib to use in combination with dexamethasone for patients with relapsed/refractory multiple myeloma, according to Amgen, the manufacturer of the proteasome inhibitor. The approval is based on results from the phase III ARROW study, in which carfilzomib administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged progression-free survival (PFS) … (leggi tutto)